Abstract Library

#4305 Lower dose of lenvatinib is similarly effective as higher dose for patients (pts) with advanced neuroendocrine tumours (NETs): A multinational retrospective cohort

Introduction: A phase II trial with lenvatinib 24mg PO daily was effective for pts with gastroenteropancreatic (GEP) NETs but led to significant toxicity. In clinical practice, dose reductions are commonly required.

Conference:

Presenting Author: Riechelmann R

Authors: Zanetta G, Grozinsky-Glasberg S, Bel-Ange A, Barros M, Felismino T,

Keywords: lenvatinib, neuroendocrine tumour, dose optimisation, toxicity,

#4168 BRCA gene mutations and NEN – Is it just random or a meaningful coincidence?

Introduction: A BRCA mutation denotes a genetic alteration found in either the BRCA1 or BRCA2 genes, both of which function as tumor suppressors. BRCA mutations are widely acknowledged for their link to breast and ovarian cancers, and rarely, to other malignancies such as the pancreas and prostate. Noteworthy, there have been limited reports associating BRCA mutations with NEN, and no possible co-relation to certain racial/ethnic populations has been reported to date.

Conference:

Presenting Author: Bel-Ange A

Authors: Bel-Ange A, Maimon O, Grozinsky-Glasberg S,

Keywords: BRCA gene mutation, NEN-neuroendocrine neoplasm,

#4156 Status of the ongoing SORENTO clinical trial: Assessing efficacy and safety of high-exposure octreotide subcutaneous depot in patients with GEP-NET

Introduction: Somatostatin receptor ligands (SRLs) are first-line standard of care therapies for gastroenteropancreatic neuroendocrine tumors (GEP-NET). Retrospective data suggest higher-dose SRLs may benefit patients with GEP-NET.

Conference:

Presenting Author: Singh S

Authors: Singh S, Capdevila J, Ang Chan J, de Herder W, Grozinsky-Glasberg S,

Keywords: CAM2029, GEP-NET, high plasma exposure, octreotide, randomised active-controlled, somatostatin receptor ligands, SORENTO,

#3961 Enhancer heterogeneity of lung carcinoids reveals sensitivity to FGF signaling inhibition

Introduction: Well-differentiated low grade lung carcinoids are histo-pathologically classified as typical and atypical, but each subtype is still heterogenous both at the molecular level and its clinical manifestation. Therefore, the treatment of these patients is challenging. The two main challenges are the lack of effective drug treatments and the lack of reliable biomarkers to guide management since the disease in patients with the same tumor grade/stage often has different clinical courses. The genetic, epigenetic, and developmental programs that drive lung carcinoids remain obscure, limiting our abilities to suggest new biomarkers and drug targets.

Conference:

Presenting Author: Drier Y

Authors: Davis E, Avniel-Polak S, Hecht M, Grozinsky-Glasberg S, Drier Y,

Keywords: FGF Signaling, Lung carcinoids, Enhancers,

#3792 Validation of a single time-point estimates of 177Lu-PRRT absorbed doses and impact on patient management for 192 therapies

Introduction: Dosimetry calculation after 177Lu-DOTA-TATE Peptide Receptor Radionuclide Therapy (PRRT) enables to estimate radiation doses absorbed by normal organs and target lesions. Previously, we described a newly developed model to predict absorbed doses (ADs) from a single post-treatment study with good accuracy as compared to the standard multiple time-points protocol.

Conference:

Presenting Author:

Authors: Chicheportiche A, Krausz Y, Godefroy J, Gross D, Grozinsky-Glasberg S,

Keywords: PRRT, Dosimetry, SPECT/CT, Single time-point,